selective RORgt inverse agonist

entered clinical dev. (psoriasis), discontinued

from HTS and SBDD

ACS Med. Chem. Lett., Apr. 10, 2020

Bristol Myers Squibb, Princeton, NJ

BMS-986251 is an inverse agonist of RORgt, a hot target in inflammation for a significant period. Unfortunately it looks like development hit a wall in this space, and several publications…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.